-
EBioMedicine Sep 2015
Topics: Acute Kidney Injury; Animals; Kidney; Male; Meclizine; Mice; Reperfusion Injury
PubMed: 26501091
DOI: 10.1016/j.ebiom.2015.09.016 -
The Consultant Pharmacist : the Journal... Apr 2015Few studies have examined racial differences in potentially inappropriate medication use. The objective of this study was to examine racial disparities in using...
OBJECTIVE
Few studies have examined racial differences in potentially inappropriate medication use. The objective of this study was to examine racial disparities in using prescription and/or nonprescription anticholinergics, a type of potentially inappropriate medication, over time.
DESIGN
Longitudinal.
SETTING
Data from the Health, Aging, and Body Composition Study (years 1, 5, and 10).
PARTICIPANTS
Three thousand fifty-five community-dwelling older adults, both blacks and whites, at year 1.
MAIN OUTCOME MEASURE
Highly anticholinergic medication use per the 2012 American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.
RESULTS
Blacks represented 41.4% of the participants at year 1. At year 1, 13.4% of blacks used an anticholinergic medication compared with 17.8% of whites, and this difference persisted over the ensuing 10-year period. Diphenhydramine was the most common anticholinergic medication reported at baseline and year 5, and meclizine at year 10, for both races. Controlling for demographics, health status, and access to care factors, blacks were 24% to 45% less likely to use any anticholinergics compared with whites over the years considered (all P < 0.05).
CONCLUSION
The use of prescription and/or nonprescription anticholinergic medications was less common in older blacks than whites over a 10-year period, and the difference was unexplained by demographics, health status, and access to care.
Topics: Aged; Black People; Cholinergic Antagonists; Drug Utilization; Female; Humans; Male; White People
PubMed: 25893702
DOI: 10.4140/TCP.n.2015.240 -
AAPS PharmSciTech Oct 2015
Topics: Administration, Oral; Biological Availability; Dextromethorphan; Guaifenesin; Humans; Hydrogen-Ion Concentration; Meclizine; Nonprescription Drugs; Phenazopyridine; Solubility; Technology, Pharmaceutical
PubMed: 25680355
DOI: 10.1208/s12249-015-0297-x -
International Scholarly Research Notices 2014The intention of present research is to formulate and develop the meclizine hydrochloride fast dissolving tablets using sublimation method to enhance the dissolution...
The intention of present research is to formulate and develop the meclizine hydrochloride fast dissolving tablets using sublimation method to enhance the dissolution rate. In this study an attempt was made to fasten the drug release from the oral tablets by incorporating the superdisintegrants and camphor as sublimating agent. The prepared fast dissolving tablets were subjected to precompression properties and characterized for hardness, weight variation, friability, wetting time, water absorption ratio, and disintegration time. From in vitro release studies, the formulation F9 exhibited fast release profile of about 98.61% in 30 min, and disintegration time 47 sec when compared with other formulations. The percent drug release in 30 min (Q 30) and initial dissolution rate for formulation F9 was 98.61 ± 0.25%, 3.29%/min. These were very much higher compared to marketed tablets (65.43 ± 0.57%, 2.18%/min). The dissolution efficiency was found to be 63.37 and it is increased by 1.4-fold with F9 FDT tablets compared to marketed tablets. Differential scanning calorimetry and Fourier transform infrared spectroscopy studies revealed that there was no possibility of interactions. Thus the development of meclizine hydrochloride fast dissolving tablets by sublimation method is a suitable approach to improve the dissolution rate.
PubMed: 27355021
DOI: 10.1155/2014/281376